We are international
Donate
TEXT SIZE   


International Myeloma Workshop 2011
PLENARY ABSTRACT SESSION II
Dr. Richardson - A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose (MTD), safety, and efficacy of pomalidomide (POM) alone or in combination with low-dose dexamethasone (DEX) in patients (PTS) with relapsed and refractory Multiple Myeloma (RRMM) who have received prior treatment (TX) that includes lenalidomide (LEN) and bortezomib (BORT)
Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
May 3-6, 2011
Paris, France
05.06.11
 related articles